B Mirror Desk: Beacon Pharmaceuticals, a publicly traded company, has been accused of “defrauding ordinary investors,” as reported by a recent article in an English newspaper. In response, the company reached out to the Dhaka Stock Exchange (DSE) for clarification regarding the claims made in the publication.

This information was disclosed by sources within the DSE.

According to these sources, the company replied to the DSE’s inquiry by emphasizing its status as a publicly listed entity. They highlighted their commitment to transparency through regular publication of financial reports and price-sensitive information. Furthermore, the company provides a comprehensive overview of its financial performance and other pertinent disclosures in its annual report.

Concerning transactions with Beacon Medicare, the company stated that these sales are conducted as part of their strategic and technical collaboration, fully adhering to the relevant regulations of the exchange.